Companies › Shenzhen Wingor Biotechnology
1 active drug program in 3 registered trials: 2 Phase 2, 1 Phase 1; Neurology, Metabolic and endocrine; next expected readout May 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| hUC-MSCs treatment (high dose) Human umbilical cord mesenchymal stem cells | – | Phase 2 | Acute Ischemic Stroke AIS; Premature Ovarian Insufficiency | May 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07084012 | hUC-MSCs treatment (high dose) | Phase 2 | Acute Ischemic Stroke AIS | Neurology | May 2027 |
| NCT07084012 | hUC-MSCs treatment (high dose) | Phase 2 | Acute Ischemic Stroke AIS | Neurology | May 2027 |
| NCT07775391 | hUC-MSCs treatment (high dose) | Phase 1 | Premature Ovarian Insufficiency | Metabolic and endocrine | Sep 2028 |
No annotated target.
–
NeuroBiogen Corxel Pharmaceuticals Urovant Sciences MediciNova PRG Science & Technology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.